Drug Profile
Research programme: cancer therapeutics - Liminal BioSciences
Alternative Names: PBI-0110; PBI-1522; PBI-1668; PBI-1737Latest Information Update: 14 Oct 2019
Price :
$50
*
At a glance
- Originator ProMetic Life Sciences
- Developer Liminal BioSciences
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Pancreatic cancer; Prostate cancer
Most Recent Events
- 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Canada (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pancreatic-cancer in Canada (PO)